AYTU logo

Aytu BioPharma, Inc. Stock Price

NasdaqCM:AYTU Community·US$23.2m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

AYTU Share Price Performance

US$2.28
0.78 (52.00%)
US$12.50
Fair Value
US$2.28
0.78 (52.00%)
81.8% undervalued intrinsic discount
US$12.50
Fair Value
Price US$2.28
AnalystHighTarget US$12.50

AYTU Community Narratives

AnalystHighTarget·
Fair Value US$12.5 81.8% undervalued intrinsic discount

Major Depressive Disorder Catalyst Will Drive Strong Long Term Upside Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Trending Discussion

Updated Narratives

AYTU logo

Major Depressive Disorder Catalyst Will Drive Strong Long Term Upside Potential

Fair Value: US$12.5 81.8% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet and fair value.

3 Risks
2 Rewards

Aytu BioPharma, Inc. Key Details

US$63.7m

Revenue

US$20.7m

Cost of Revenue

US$43.0m

Gross Profit

US$56.3m

Other Expenses

-US$13.3m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-1.31
67.56%
-20.90%
117.3%
View Full Analysis

About AYTU

Founded
n/a
Employees
83
CEO
Joshua Disbrow
WebsiteView website
aytubio.com

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Recent AYTU News & Updates

Recent updates

No updates